JP2006506455A - ウイルス感染症の治療のための1−アシル−ピロリジン誘導体 - Google Patents

ウイルス感染症の治療のための1−アシル−ピロリジン誘導体 Download PDF

Info

Publication number
JP2006506455A
JP2006506455A JP2005501534A JP2005501534A JP2006506455A JP 2006506455 A JP2006506455 A JP 2006506455A JP 2005501534 A JP2005501534 A JP 2005501534A JP 2005501534 A JP2005501534 A JP 2005501534A JP 2006506455 A JP2006506455 A JP 2006506455A
Authority
JP
Japan
Prior art keywords
tert
pyrrolidine
butylbenzoyl
methoxy
isobutyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005501534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506455A5 (https=
Inventor
デイビッド・ハイ
チャールズ・デイビッド・ハートリー
ピーター・デイビッド・ハウズ
デボラ・リネット・ジャクソン
プリトム・シャー
マーティン・ジョン・スレイター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0224774A external-priority patent/GB0224774D0/en
Priority claimed from GB0229470A external-priority patent/GB0229470D0/en
Priority claimed from GB0317141A external-priority patent/GB0317141D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2006506455A publication Critical patent/JP2006506455A/ja
Publication of JP2006506455A5 publication Critical patent/JP2006506455A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
JP2005501534A 2002-10-24 2003-10-22 ウイルス感染症の治療のための1−アシル−ピロリジン誘導体 Withdrawn JP2006506455A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0224774A GB0224774D0 (en) 2002-10-24 2002-10-24 Compounds
GB0229470A GB0229470D0 (en) 2002-12-18 2002-12-18 Compounds
GB0317141A GB0317141D0 (en) 2003-07-22 2003-07-22 Compounds
PCT/EP2003/011813 WO2004037818A1 (en) 2002-10-24 2003-10-22 1-acyl-pyrrolidine derivatives for the treatment of viral infections

Publications (2)

Publication Number Publication Date
JP2006506455A true JP2006506455A (ja) 2006-02-23
JP2006506455A5 JP2006506455A5 (https=) 2006-12-07

Family

ID=32180212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005501534A Withdrawn JP2006506455A (ja) 2002-10-24 2003-10-22 ウイルス感染症の治療のための1−アシル−ピロリジン誘導体

Country Status (18)

Country Link
US (1) US7304087B2 (https=)
EP (1) EP1554274B1 (https=)
JP (1) JP2006506455A (https=)
KR (1) KR20050057670A (https=)
AR (1) AR041816A1 (https=)
AT (1) ATE418554T1 (https=)
AU (1) AU2003276172A1 (https=)
BR (1) BR0315417A (https=)
CA (1) CA2503471A1 (https=)
CO (1) CO5550450A2 (https=)
DE (1) DE60325498D1 (https=)
IS (1) IS7851A (https=)
MA (1) MA27524A1 (https=)
MX (1) MXPA05004435A (https=)
NO (1) NO20052472L (https=)
PL (1) PL376454A1 (https=)
TW (1) TW200418848A (https=)
WO (1) WO2004037818A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0304494D0 (en) * 2003-02-27 2003-04-02 Glaxo Group Ltd Compounds
GB0408995D0 (en) * 2004-04-22 2004-05-26 Glaxo Group Ltd Compounds
GB0423673D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
GB0423672D0 (en) * 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
JP4663733B2 (ja) * 2004-10-29 2011-04-06 シェーリング コーポレイション 抗ウイルス物質としての置換5−オキソピラゾールおよび置換[1,2,4]トリアゾール
GB0519478D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519488D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519486D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
GB0519485D0 (en) * 2005-09-23 2005-11-02 Glaxo Group Ltd Compounds
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
US20090053175A1 (en) * 2007-08-24 2009-02-26 Yat Sun Or Substitute pyrrolidine derivatives
EP2272832A4 (en) 2008-04-28 2011-09-07 Asahi Kasei Pharma Corp PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF
JP2011530562A (ja) 2008-08-11 2011-12-22 グラクソスミスクライン エルエルシー アレルギー性、炎症性及び感染性疾患治療用のプリン誘導体
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
SI2320905T1 (sl) 2008-08-11 2017-10-30 Glaxosmithkline Llc Corporation Service Company Novi adeninski derivati
EP2534149B1 (en) 2010-02-10 2014-10-15 GlaxoSmithKline LLC 6-amino-2-{[(1s)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)pentyl]-7,9-dihydro-8h-purin-8-one maleate
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
WO2013134012A1 (en) 2012-03-06 2013-09-12 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
MX2017006302A (es) 2014-11-13 2018-02-16 Glaxosmithkline Biologicals Sa Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
TWI704154B (zh) 2015-12-03 2020-09-11 英商葛蘭素史克智慧財產發展有限公司 新穎化合物
HRP20220936T1 (hr) 2016-04-07 2022-10-28 Glaxosmithkline Intellectual Property Development Limited Heterociklički amidi korisni kao modulatori proteina
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
CA3077337A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting)
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP2022533194A (ja) 2019-05-16 2022-07-21 スティングセラ インコーポレイテッド ベンゾ[b][1,8]ナフチリジン酢酸誘導体および使用方法
US20220227761A1 (en) 2019-05-16 2022-07-21 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CN114981265B (zh) 2019-12-18 2025-01-03 Ctxt私人有限公司 化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5687396A (en) 1995-04-21 1996-11-07 Novarits Ag N-aroylamino acid amides as endothelin inhibitors
AU1804299A (en) 1997-12-08 1999-06-28 Glycomed Incorporated Sialyl lewis x and sialyl lewis a glycomimetics
ATE391451T1 (de) 1998-01-26 2008-04-15 Massachusetts Inst Technology Endoskop zur erfassung von fluoreszenzbilder
EP1315698A1 (en) 1998-04-23 2003-06-04 Abbott Laboratories Pyrrolidines as inhibitors of neuraminidases
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1118287B1 (de) * 2000-01-21 2004-11-24 Alois Ing. Sampl Steckbares Regalsystem
EP1278743A4 (en) * 2000-05-05 2003-05-14 Smithkline Beecham Corp NEW ANTI-INFECTIOUS ACTIVE SUBSTANCES
WO2002044168A2 (en) 2000-11-20 2002-06-06 Scios Inc. Indole-type inhibitors of p38 kinase
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ グループ リミテッド Hcv阻害剤としてのアシルジヒドロピロール誘導体
CA2490385C (en) 2002-10-28 2014-05-06 Marquage Antivol Sherlock, Inc. Method of preventing theft of vehicles using intensive marking

Also Published As

Publication number Publication date
AR041816A1 (es) 2005-06-01
DE60325498D1 (de) 2009-02-05
PL376454A1 (en) 2005-12-27
ATE418554T1 (de) 2009-01-15
KR20050057670A (ko) 2005-06-16
CO5550450A2 (es) 2005-08-31
US20060258720A1 (en) 2006-11-16
EP1554274A1 (en) 2005-07-20
MA27524A1 (fr) 2005-09-01
US7304087B2 (en) 2007-12-04
TW200418848A (en) 2004-10-01
AU2003276172A1 (en) 2004-05-13
EP1554274B1 (en) 2008-12-24
NO20052472L (no) 2005-05-23
WO2004037818A1 (en) 2004-05-06
CA2503471A1 (en) 2004-05-06
MXPA05004435A (es) 2005-07-26
BR0315417A (pt) 2005-08-16
IS7851A (is) 2005-05-19

Similar Documents

Publication Publication Date Title
US7304087B2 (en) 1-acyl-pyrrolidine derivatives for the treatment of viral infections
US20050043545A1 (en) 4-(5-Membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005515172A (ja) Hcv阻害剤としての4−(6−員)−ヘテロアリールアシルピロリジン誘導体
US20070270475A1 (en) 4-Methoxy-Pyrrolidine-2-Carboxylic Acid Compounds and Derivatives Thereof as Hepatitis C Virus Inhibitors
US20050009873A1 (en) Acyl dihydro pyrrole derivatives as hcv inhibitors
WO2004096210A1 (en) Acylated indoline and tetrahydroquinoline derivatives as hcv inhibitors
JP2007533693A (ja) Hcv阻害剤としてのアシルジヒドロピロール誘導体
WO2007039142A1 (en) C (2) -heteroarylmethyl-c (4) -methoxymethyl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus
WO2007039145A1 (en) C (2) -heteroarylmethyl-c (4) -pyrazinyl-2-yl acyl pyrrolidine compounds and their use for treating viral infections, especially hepatitis c virus
US20050176801A1 (en) Acyl bicyclic derivatives of pyrrol
US20090227600A1 (en) 4-(pyrazine-2-yl) -pyrrolidine -2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
WO2004009543A2 (en) 1-carbonyl-4-cyano-pyrrolidine-2-carboxylic acid derivatives as hepatitis c virus inhibitors
WO2005079799A1 (en) 4-acyl-piperazines as anti-viral agents
WO2006100106A1 (en) 3-carboxy pyrroles as anti-viral agents
WO2004076415A1 (en) 1- (hetero)aroyl-pyrrolidine-2-carboxylic acid derivatives useful as anti.viral agents
WO2007039144A1 (en) Pyrrolidine derivatives for treating viral infections
WO2007039143A1 (en) C (2) -heteroarylmethyl-c (4) -pyrazin-2-yl acyl pyrrolidine compounds and their user for treating viral infections, especially hepatitics c (hcv)
ZA200502945B (en) 1-Acyl-pyrrolidine derivatives for the treatment of viral infections.
WO2004060889A1 (en) 5-thiazole substituted 2-pyrrolidine-carboxylic acids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061023

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090428